Steroid-Induced Serous Retinal Detachment in a Patient with Polymyalgia Rheumatica

Hironori Takahashi¹, Yuka Kasuya¹, Shinji Makino¹

¹Department of Ophthalmology, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan

**Abstract**

An 82-year-old man with polymyalgia rheumatica was referred for ophthalmological examination. On ophthalmic examination, his best-corrected visual acuity (BCVA) was 20/40 in the right eye and 20/20 in the left eye. Fundus examination was unremarkable in the left eye, but epiretinal membrane was observed in the right eye. There was no SRD on optical coherence tomography (OCT) in the right eye. The patient was treated with oral prednisolone (10 mg daily), and his symptoms subsided rapidly. However, 1 week after the administration of prednisolone, his right BCVA deteriorated to 40/200. OCT showed serous retinal detachment (SRD) involving the fovea in the right eye. We diagnosed our patient with steroid-induced SRD. SRD gradually improved with the reduction of the prednisolone dose. Clinicians should be aware of CSC development after glucocorticoid therapy. If possible, the glucocorticoid should be discontinued and replaced by an alternative.

**Keywords**: polymyalgia rheumatica, glucocorticoid therapy, optical coherence tomography.

**INTRODUCTION**

Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease in older individuals and a common indication for long-term corticosteroid therapy [1, 2]. Glucocorticoid therapy is a well-known risk factor for central serous chorioretinopathy (CSC), and exogenous glucocorticoids may cause CSC regardless of their route of administration, dosage, and duration [3-5].

Here, we report a case of steroid-induced serous retinal detachment (SRD) in an 82-year-old man with polymyalgia rheumatica.

**CASE REPORT**

An 82-year-old man with PMR was referred for ophthalmological examination. His diagnosis of PMR was based on the following 2012 provisional classification criteria for PMR [1]: Morning stiffness duration > 45 min, hip pain and limited range of motion, hip tenderness, shoulder pain and limited range of motion, shoulder tenderness, abnormal C-reactive protein level (20.14 mg/L) and erythrocyte sedimentation rate (131 mm/h), negative rheumatoid factor, and negative anticitrullinated protein antibody. There were no visual symptoms. On ophthalmic examination, his best-corrected visual acuity (BCVA) was 20/40 in the right eye and 20/20 in the left eye. Slit-lamp examination revealed mild bilateral cortical opacities of the lens. Fundus examination was unremarkable in the left eye, but epiretinal membrane was observed in the right eye. There was no SRD on optical coherence tomography (OCT) in the right eye (Figure 1A). The patient was treated with oral prednisolone (10 mg daily), and his symptoms subsided rapidly. However, 1 week after the administration of prednisolone, his right BCVA deteriorated to 40/200. OCT showed SRD involving the fovea in the right eye (Figure 1B). We diagnosed our patient with steroid-induced SRD.
Fig. 1: Optical coherence tomography images of the right eye in horizontal directions

The direction is shown in each inset. A: Initial visit; Serous retinal detachment (SRD) is not shown. B: One week after the administration of prednisolone; Marked SRD is developed.

Fluorescein angiography confirmed the diagnosis of CSC based on leakage with the diffusion of the fluorescein.

Fig. 2: Fluorescein angiography of the right eye A: early phase, B: late phase

Note leakage with diffusion of the fluorescein and detachment of the macular retina. SRD gradually improved with the reduction of the prednisolone dose.

**DISCUSSION**

In this study, we present a case of steroid-induced SRD in an 82-year-old man with PMR. To our knowledge, there is only three reports of CSC associated with PMR [3, 6, 7].

PMR is a common inflammatory rheumatic disease in older individuals and a common indication for long-term corticosteroid therapy [1, 2]. Glucocorticoid therapy is a well-known risk factor for CSC, and exogenous glucocorticoids may cause CSC regardless of their route of administration, dosage, and duration [3-5]. The risk exists with oral dosages of only 10–15 mg/day, regardless of treatment duration. The time from glucocorticoid exposure to CSC development ranges from a few days to several years.

The pathophysiology of glucocorticoid-induced CSC involves mineralocorticoid receptors found on the choroid blood vessels, which have a high affinity for glucocorticoids. The binding of glucocorticoids to these receptors increases the permeability of the choroid and induces small breaks in the retinal pigment epithelium, allowing choroidal fluid to accumulate beneath the retina [3-5]. Most patients with glucocorticoid-induced CSC experience resolution of their symptoms with full recovery of their previous vision within a few months after glucocorticoid discontinuation [3-7].

**CONCLUSION**

Although the findings were based on a single case, clinicians should be aware of CSC development after glucocorticoid therapy. If possible, the glucocorticoid should be discontinued and replaced by an alternative.
Disclosure

The author declares no conflict of interest.

REFERENCES


